 |
|
|
| |
SAPPHIRE-I Subpopulation Analysis: ABT-450/r/Ombitasvir (ABT-267), Dasabuvir (ABT-333), and Ribavirin Regimen Achieves High Sustained Virologic Response Rates 12 Weeks Post-treatment in Treatment-naïve Patients With Chronic HCV GT 1 Infection, Regardless of Baseline Characteristics
|
| |
| |
Reported by Jules Levin
Presented at the 20th International AIDS Conference, 20-25 July, 2014, Melbourne, Australia
Stephen D Shafran1, Stuart Roberts2, Darrell Crawford3, Victor de Ledinghen4, Stephen D Ryder5, Lorenzo Magenta6, Lisa Nyberg7, Vinod Rustgi8, Kris V Kowdley9, Junyuan Xiong10, Eoin Coakley10, Lois Larsen10, Thomas Podsadecki10
1University of Alberta Hospital, Edmonton, Alberta, Canada; 2The Alfred Hospital, Melbourne, Victoria, Australia; 3Greenslopes Private Hospital, Greenslopes, Queensland, Australia; 4Hopital Haut Leveque, CHU Bordeaux, Pessac, France; 5Notti ngham University Hospitals NHS Trust, Nottingham, United Kingdom;
6Epatocentro Ticino, Lugano, Switzerland; 7Kaiser Permanente, San Diego, California, United States; 8Metropolitan Research, Fairfax, Virginia, United States; 9Digestive Disease Institute, Virginia Mason Medical Center, Seattle, Washington, United States; 10AbbVie Inc., North Chicago, Illinois, United States
These are links to the phase 3 studies reported at EASL in April including for this subpopulation analysis of the SAPPHIRE-1 Study:
EASL: SAPPHIRE-I: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 631 TREATMENT-NAïVE ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/11/14)
EASL: SAPPHIRE-II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 394 TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/10/14)
EASL: TURQUOISE-II: SVR12 RATE OF 92-96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/r/ABT-267 AND ABT-333 PLUS RIBAVIRIN - (04/14/14)
|
| |
|
|
|
|
|
